|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The baseline characteristics were similar between groups, with the exception of a greater prevalence of 1-vessel coronary artery disease and clopidogrel or dual antiplatelet therapy at the time of surgery in the PCI + MIVS group, and more 3-vessel coronary artery disease in those undergoing CABG + valve surgery.
|
28740710 |
2017 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The baseline characteristics were similar between groups, with the exception of a greater prevalence of 1-vessel coronary artery disease and clopidogrel or dual antiplatelet therapy at the time of surgery in the PCI + MIVS group, and more 3-vessel coronary artery disease in those undergoing CABG + valve surgery.
|
28740710 |
2017 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The primary device-oriented endpoint (Target Lesion Failure, TLF) was defined as a combination of cardiovascular death, target vessel myocardial infarction or clinically driven target lesion revascularization.Among the cardiac risk factors, NSTE-ACS patients were more frequently smokers (P = 0.028), had less frequently dyslipidemia (P = 0.003) and a history of prior PCI (P < 0.01).The median follow-up was 1070[763-1197] days.
|
29630530 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We examined the effect of Ad CEA-N116Y on the metastatic growth of PCI-43 colonies in liver, which was generated by tumor injection into the spleen of nude mice.
|
10757026 |
2000 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The STS stroke risk model was surprisingly more discriminating in PCI compared to CABG EXCEL patients.
|
31422924 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Compared to CL-PCI, MV-PCI was associated with a similar risk of bleeding (OR 1.13; 95% CI 0.91-1.40) and stroke (OR 1.28; 95% CI 0.84-1.96), but a higher risk of developing renal failure (OR 1.32; 95% CI 1.05-1.65).
|
30593731 |
2019 |
|
Acute myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cardiovascular death, acute myocardial infarction (AMI), or PCI at 1year was assessed using multivariate logistic regression analysis.
|
29220755 |
2018 |
|
Acute myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty-two patients with AMI successfully treated with primary PCI underwent cardiovascular magnetic resonance after 4-6 days and 3 months.
|
28644903 |
2017 |
|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RENAMI project is a multicenter retrospective observational registry enrolling 4424 patients with ACS treated with PCI and prasugrel or ticagrelor plus aspirin.
|
30228021 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> In 582 consecutive patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) scheduled for PCI and treated with ASA and Clopidogrel, Prasugrel, or Ticagrelor, SNP analysis for rs12566888, rs2768759, rs41273215, rs3737224, and rs822442 was performed.
|
29867494 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CRUSADE and ACTION scores had a greater calibration and discrimination for in-hospital major bleeding compared with the ACUITY-HORIZONS score in Chinese patients with ACS undergoing PCI.
|
28491083 |
2017 |
|
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> In 582 consecutive patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) scheduled for PCI and treated with ASA and Clopidogrel, Prasugrel, or Ticagrelor, SNP analysis for rs12566888, rs2768759, rs41273215, rs3737224, and rs822442 was performed.
|
29867494 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Door-to-balloon (DTB) time ≤90 min is an important quality indicator in the management of ST-elevation myocardial infarction (STEMI), but a considerable number of patients still do not meet this goal, particularly in countries outside the USA and Europe.Methods and Results:We analyzed 2,428 STEMI patients who underwent primary PCI ≤12 h of symptom onset who were registered in an ongoing prospective multicenter database (JCD-KiCS registry), between 2008 and 2013.
|
28228609 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this single-center prospective randomized study, patients with subacute STEMI presenting ≥12 and ≤48 h after symptom onset were randomized to primary PCI with or without manual TA in a 1:1 ratio.
|
29869443 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Low risk patients identified using CADILLAC risk score with STEMI treated successfully with primary PCI have a low adverse event rate on the third day or later of hospitalization suggesting that an earlier discharge is safe in properly selected patients.
|
27896906 |
2017 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
|
24952855 |
2014 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We chose the acute ST-elevation myocardial infarction (ASTEMI) patients treated with direct PCI to compare different administration routes of diltiazem.
|
30223281 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This paper presents a constructive critical appraisal of 7 key studies: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), VEST (Vest Prevention of Early Sudden Death Trial), SECURE-PCI (Statins Evaluation in Coronary Procedures and Revascularization), TREAT (Ticagrelor in Patients with ST-Elevation Myocardial Infarction treated with Pharmacological Thrombolysis), POISE (PeriOperative ISchemic Evaluation), SMART-DATE (Safety of 6-Month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome), and CVD-REAL 2 (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors).
|
29753563 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred seventeen patients with STEMI and undergoing pPCI were randomly divided into the sustained nicorandil group (5 mg, three times daily) or the control group (only single nicorandil before PCI).
|
30821716 |
2019 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analysed the proportion of patients with ST-elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention within 90 minutes (primary PCI), the proportion of patients with hip fracture (HF) who underwent surgery within 2 days, and the proportion of women with primary C-section.
|
29584783 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we compared the outcome of conscious survivors of OHCA presenting with ST-elevation myocardial infarction (STEMI) in post-resuscitation electrocardiogram undergoing immediate invasive coronary strategy with randomly selected STEMI patients without preceding OHCA undergoing primary PCI.
|
30244190 |
2018 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS).
|
31812224 |
2020 |
|
ST segment elevation myocardial infarction
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AT1R (rs 5182) CT genotype is mildly associated with STEMI (OR = 1.1), but also prone to have PCI after ACS attack (OR = 1.6) while TT genotype has a risk to get less improvement (OR = 1.8).
|
31195108 |
2020 |